Phosphatidylethanolamine (18:2e/18:2) may inhibit adipose tissue wasting in patients with cancer cachexia by increasing lysophosphatidic acid receptor 6

•Cancer Cachexia Dynamics: Profound lipid alterations unveiled in subcutaneous and visceral adipose tissues.•Ceramide Imbalance: Cachectic patients exhibit elevated Ceramide levels, underscoring lipid dysregulation.•LPAR6 Modulation: LPAR6 emerges as a pivotal player, elevated in both adipose tissue...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nutrition (Burbank, Los Angeles County, Calif.) Los Angeles County, Calif.), 2024-04, Vol.120, p.112356-112356, Article 112356
Hauptverfasser:	Ding, Zuoyou, Han, Jun, Huang, Qiuyue, Liu, Xiao, Sun, Diya, Sui, Xiangyu, Zhuang, Qiulin, Wu, Guohao
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase Adipocyte lipolysis Adipocytes Adipose tissue AKT protein Bioinformatics Biomarkers Biosynthesis Body fat Cachexia Cancer Cancer therapies ceramides Chemotherapy Chromatography Discriminant analysis Gene expression gene expression regulation genes Glycosylphosphatidylinositol interleukin-6 Lipid metabolism lipidomics Lipids LPAR6 Lysophosphatidic acid lysophospholipids Mass spectrometry Medical prognosis Melanoma Metabolites Molecular docking multivariate analysis Multivariate statistical analysis muscles nutrition Patients PE(18:2e/18:2) Phosphatidylethanolamine phosphatidylethanolamines Proteins Quality of life Receptors Scientific imaging Signal transduction Software Statistical analysis therapeutics Transcriptomics Weight control Weight loss Western blotting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!